InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement with Lyvgen Biopharma, a Shanghai-based specialist in immuno-oncology therapeutics. According to the agreement, Lyvgen will transfer proprietary technology related to no more than three target antibodies to InventisBio, along with licensing patent rights and other associated materials. The transaction is valued at up to RMB 1.5 million (USD 0.2 million), marking a significant collaboration in the field of immuno-oncology.
This agreement signifies a strategic move for InventisBio to bolster its portfolio with innovative immuno-oncology assets, while providing Lyvgen Biopharma with a valuable opportunity to monetize its proprietary technology. The deal underscores the growing activity in China’s biopharmaceutical sector and the increasing focus on immuno-oncology as a critical area for cancer treatment and research.
The collaboration between InventisBio and Lyvgen Biopharma highlights the potential for synergies between companies in the development of novel therapies and the commercialization of cutting-edge medical solutions.- Flcube.com
